Q-omics provides the consensus-scored TIMM8A profile across patient tissues and cancer cell-line models. TIMM8A expression is associated with patient survival in 31 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TIMM8A is differentially expressed in 15, with the highest sampling consensus in LUAD. Additionally, TIMM8A protein abundance shows 23,387 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, LUAD, and LSCC as cancer lineages where TIMM8A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TIMM8A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TIMM8A survival associations across molecular data types. TIMM8A RNA expression shows survival associations in the most cancer types (31), followed by mutation status (1) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TIMM8A RNA expression–survival associations across cancer types. High TIMM8A expression shows unfavorable associations in KIRP, BRCA, ACC, UCEC and KICH, but favorable associations in OV. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TIMM8A RNA expression.
This table summarizes TIMM8A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 8. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TIMM8A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TIMM8A shows higher tumor expression in LUAD, BLCA, COAD, STAD, LUSC and HNSC. The LUAD box plot shows higher TIMM8A RNA expression in tumor versus normal tissue (log2 FC = +1.201, t-test p < 0.001).
This table shows molecular features associated with TIMM8A in patient tissues and cancer cell lines. In patient samples, TIMM8A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TIMM8A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Lymphoma.
